FDA grants orphan drug status for CSL Behring rIX-FP
The designation was granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). CSL Behring research and development senior vice
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.